Literature DB >> 8780933

Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in astrocytic gliomas and their correlation to cell proliferation.

K Dietzmann1, P von Bossanyi, J Sallaba, E Kirches, H J Synowitz, M Warich-Kirches.   

Abstract

The aim of this report was to investigate the expression of the p53 and mdm-2 oncoproteins in astrocytic gliomas and to assess their interrelation to proliferating activities. Using monoclonal antibodies directed against p53 and mdm-2, these proteins were stained immunohistochemically in 60 astrocytic brain tumors with different histologic grade. Positive p53 stained nuclei were detected in 25.4% of the tumor cases. Mdm-2 staining products were only localized in 10.5% of specimens. Significant correlations could be found between p53, MIB-1, PCNA and mitotic index on the one hand, and tumor grade on the other hand. There were no clear relations between mdm-2 expression and proliferation markers. The grade of ploidy has a lower priority for the proliferating activity. In most cases mdm-2 immunoreactivity was strongly associated with a low or negative p53 expression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780933

Source DB:  PubMed          Journal:  Gen Diagn Pathol        ISSN: 0947-823X


  3 in total

1.  Alterations of p53, BCL-2, and hMSH2 protein expression in the normal brain tissues, gliosis, and gliomas.

Authors:  Mahmoud R Hussein; Rabab M H El-Ghorori; Yasser G Abd El-Rahman
Journal:  Int J Exp Pathol       Date:  2006-08       Impact factor: 1.925

2.  Apoptosis and proliferation: correlation with p53 in astrocytic tumours.

Authors:  Chitra Sarkar; Asis Kumar Karak; Neera Nath; Mehar Chand Sharma; Ashok Kumar Mahapatra; Parthoprasad Chattopadhyay; Subrata Sinha
Journal:  J Neurooncol       Date:  2005-06       Impact factor: 4.130

3.  Proliferation and apoptosis in long-term surviving low grade gliomas in relation to radiotherapy.

Authors:  Mart A A M Heesters; Jan Koudstaal; K Gwan Go; Willemina M Molenaar
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.